A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythematosus
- Status
- WITHDRAWN
- Phase
- PHASE1
Clinical Trials Related to Atara Biotherapeutics
Related studies linked through entity extraction aliases.
A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1
Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Expanded Access Protocol of ATA230 (Third-Party Donor-Derived CMV-CTLs) for the Treatment of CMV Viremia or Disease
- Status
- NO_LONGER_AVAILABLE
- Phase
- N/A
Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies
- Status
- NO_LONGER_AVAILABLE
- Phase
- N/A
Primary Transplant Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation
- Status
- COMPLETED
- Phase
- PHASE2
Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies
- Status
- COMPLETED
- Phase
- PHASE2
Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation
- Status
- COMPLETED
- Phase
- PHASE1
Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2